Home/Pipeline/AfriMab-2

AfriMab-2

Solid tumors (PD‑1 inhibition)

PreclinicalActive

Key Facts

Indication
Solid tumors (PD‑1 inhibition)
Phase
Preclinical
Status
Active
Company

About Afrigen Biologics

South African biotech delivering affordable vaccines and biosimilars using proprietary biologics platforms.

View full company profile